Anika Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $38,753 | $41,921 | $40,523 | $42,971 |
Gross Profit | 1,440 | 27,365 | 24,628 | 26,329 |
EBITDA | -25,423 | 2,219 | -1,872 | 1,983 |
EBIT | -27,611 | 161 | -4,471 | -1,608 |
Net Income | -29,918 | -88 | -4,514 | -63,000 |
Net Change In Cash | 38,753 | 41,921 | 40,523 | 42,971 |
Free Cash Flow | 3,800 | -4,472 | -1,934 | 1,798 |
Cash | 62,368 | 62,822 | 68,629 | 72,867 |
Basic Shares | 14,768 | 14,839 | 14,698 | 14,647 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $166,662 | $156,236 | $147,794 | $130,457 |
Gross Profit | 103,088 | 93,576 | 82,943 | 69,026 |
EBITDA | 2,516 | -4,913 | 2,615 | -12,829 |
EBIT | -11,701 | -19,400 | -13,373 | -27,824 |
Net Income | -82,667 | -14,859 | 4,134 | -23,982 |
Net Change In Cash | 166,662 | 156,236 | 147,794 | 130,457 |
Cost of Revenue | -7,929 | -1,500 | -61,973 | |
Free Cash Flow | -7,215 | -3,077 | 3,254 | 11,437 |
Cash | 72,867 | 86,327 | 94,386 | 95,817 |
Basic Shares | 14,656 | 14,561 | 14,634 | 14,222 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.25 |
2024-06-30 | -$0.01 |
2024-03-31 | -$0.31 |
2023-12-31 | -$4.30 |
